UK MHRA Consults on a New Regulatory Framework for Rare Disease Therapies
Read the full articleYou might also wanna read
ASO biotech wants MHRA to go further in new rare disease therapy framework
CEO of SynaptixBio thinks the MHRA could do more to support UK rare disease drug innovation.
UK Government Considers New Regulations for AI-Powered Medical Devices in Healthcare
The MHRA is seeking evidence on the regulation of AI in healthcare to inform the recommendations of the National Commission into the Regulat
gov.uk·27d agoEquity in the age of advanced therapies: insights from haemophilia
In Laurence Woollard's latest blog for Rare Disease Day, he reflects on how advanced therapies are being introduced within the NHS – highlig
Improving care for rare diseases
Rare diseases present a substantial challenge for healthcare systems, as their high clinical heterogeneity and low prevalence complicate the
ABPI welcomes new MHRA Chief Executive Officer
Lawrence Tallon has been named as the new Chief Executive Officer of Medicines and Healthcare products Regulatory Agency (MHRA).
PHRMAG and the Authority of Social Contribution - Ma’an partner to enhance Oncology and rare disease care in Abu Dhabi
Strategic collaboration aims to develop an innovative, sustainable funding model to improve access to healthcare services
Comments
Sign in to join the conversation.
No comments yet. Be the first.